James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Sell FCX Stock While the Getting Is Still Good

Patient Freeport McMoRan shareholders were finally rewarded by a big jump from FCX stock today, but the proposed solution doesn't solve the real problem.

Why Abbott Labs (ABT) SHOULD Buy St. Jude Medical (STJ)

ABT shareholders may have reason to be disappointed today -- as do STJ owners -- but this pairing could still happen in the future.

Why Schlumberger Limited (SLB), GrubHub Inc. (GRUB), and Syngenta AG (SYT) Are 3 of Today’s Worst Stocks

The marketwide rising tide didn't do Schlumberger (SLB), GrubHub (GRUB), and Syngenta (SYT) a bit of good on Wednesday.

SLB Stock: CAM Deal Is a Long-Term Play Against Low Oil Prices

Don't be fooled by the dip in SLB stock. The CAM buyout was necessary, as M&A in the sector will heat up sooner rather than later.

Despite Wednesday’s Jump, ANF Stock Still Isn’t Buy-Worthy

The 15% surge from ANF stock today ignores some key red flags buried in last quarter's accounting statements from Abercrombie & Fitch.